Expert perspective: Highlights on myeloma cell therapy from the American Society of Hematology Annual Meeting 2019. Issue 4 (19th June 2020)

• Record Type: Journal Article
• Authors: Kunacheewa, Chutima; Manasanch, Elisabet E.
• Is Part Of: Advances in cell and gene therapy. Volume 3:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-19
• Subjects: cell therapy -- multiple myeloma -- stem cell transplantation; Cellular therapy -- Periodicals; Gene therapy -- Periodicals; Immunotherapy -- Periodicals; Cancer -- Treatment -- Periodicals; Bone marrow -- Diseases -- Treatment -- Periodicals; Blood -- Diseases -- Treatment -- Periodicals; 615.5
• DOI: 10.1002/acg2.93
• Languages: English
• ISSNs: 2573-8461

Abstract

Abstract: Autologous stem cell transplantation has been part of standard of treatment in multiple myeloma for 2 decades. The data showed improving progression‐free survival and overall survival. Despite the improvement of new drugs, myeloma patients continue to relapse New cell therapy, chimeric antigen receptor T‐cell therapy have been explored in heavily pretreated patients. In this commentary, we highlight studies presented at the American Society of Hematology (ASH) Annual Meeting held in Orlando, FL in December 2019. Abstract : One possible mechanism of relapsed disease is the downregulation of surface B‐cell maturation antigen (BCMA) by gamma secretase. The gamma secretase inhibitor (JSMD194) can increase surface BCMA expression and decrease soluble BCMA.